← All trials
NCT04463251
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2020
- Primary completion
- May 14, 2021
- Completion date
- May 1, 2022
- First posted
- Jul 9, 2020
- Last posted
- Jul 9, 2020
- Enrollment
- 146
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- R-PharmLead sponsor
- R-PharmCollaborator
- Cromos Pharma, LLCCollaborator
- R-PharmStudy director
- Cromos Pharma, LLCCollaborator
- Data Management 365 LLCCollaborator
- K-ResearchCollaborator
- KeystatCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.